ASCO GUIDELINES Bundle

Biomarkers for Systemic Therapy in Metastatic Breast Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475448

Contents of this Issue

Navigation

Page 6 of 7

7 Table 1. At-A-Glance Guide to ASCO Biomarker Testing in Metastatic Breast Cancer Recommendations Biomarker Tests Recommended by the ASCO Expert Panel Test Recommendation grade • PIK3CA • Germline BRCA1 and BRCA2 • PD-L1 Strong recommendation; EB-B-H Strong recommendation; EB-B-H Strong recommendation; EB-B-I • dMMR/MSI-H • TMB • NTRK fusions Moderate recommendation; IC-L Moderate recommendation; IC-L Moderate recommendation; IC-L Biomarker Tests Not Recommended by the ASCO Expert Panel Test Recommendation grade • ESR1 • PALB2 Moderate recommendation; EB-Ins Moderate recommendation; EB-L • HRD • TROP2 expression • ctDNA • CTCs Moderate recommendation; IC-L Moderate recommendation; IC-L Moderate recommendation; IC-L Moderate recommendation; IC-L

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Biomarkers for Systemic Therapy in Metastatic Breast Cancer